Literature DB >> 28838976

Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma.

Marina Pretolani1,2,3,4, David Soussan1,2,3,4, Isabelle Poirier1,2,3, Gabriel Thabut1,2,3,5,6, Michel Aubier7,2,3,5.   

Abstract

The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm3) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts.Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score.Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28838976     DOI: 10.1183/13993003.00019-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  29 in total

Review 1.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 2.  Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis.

Authors:  Daniël A Korevaar; Guus A Westerhof; Junfeng Wang; Jérémie F Cohen; René Spijker; Peter J Sterk; Elisabeth H Bel; Patrick M M Bossuyt
Journal:  Lancet Respir Med       Date:  2015-03-20       Impact factor: 30.700

Review 3.  Evolving Concepts of Asthma.

Authors:  Marc Gauthier; Anuradha Ray; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

4.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.

Authors: 
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

5.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Authors:  Nicola A Hanania; Sally Wenzel; Karin Rosén; Hsin-Ju Hsieh; Sofia Mosesova; David F Choy; Preeti Lal; Joseph R Arron; Jeffrey M Harris; William Busse
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

Review 6.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

7.  Cluster analysis and clinical asthma phenotypes.

Authors:  Pranab Haldar; Ian D Pavord; Ruth H Green; Dominic E Shaw; Michael A Berry; Michael Thomas; Christopher E Brightling; Andrew J Wardlaw
Journal:  Am J Respir Crit Care Med       Date:  2008-05-14       Impact factor: 21.405

8.  Chronic Comorbidities Contribute to the Burden and Costs of Persistent Asthma.

Authors:  Paula Kauppi; Miika Linna; Juha Jantunen; Jaana E Martikainen; Tari Haahtela; Anna Pelkonen; Mika Mäkelä
Journal:  Mediators Inflamm       Date:  2015-12-13       Impact factor: 4.711

9.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

10.  Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.

Authors:  Jean Bousquet; Eva Mantzouranis; Alvaro A Cruz; Nadia Aït-Khaled; Carlos E Baena-Cagnani; Eugene R Bleecker; Chris E Brightling; Peter Burney; Andrew Bush; William W Busse; Thomas B Casale; Moira Chan-Yeung; Rongchang Chen; Badrul Chowdhury; Kian Fan Chung; Ronald Dahl; Jeffrey M Drazen; Leonardo M Fabbri; Stephen T Holgate; Francine Kauffmann; Tari Haahtela; Nikolaï Khaltaev; James P Kiley; Mohammad R Masjedi; Yousser Mohammad; Paul O'Byrne; Martyn R Partridge; Klaus F Rabe; Alkis Togias; Christiaan van Weel; Sally Wenzel; Nanshan Zhong; Torsten Zuberbier
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

View more
  6 in total

1.  Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort.

Authors:  Michel Aubier; Gabriel Thabut; Caroline Fabry-Vendrand
Journal:  J Asthma Allergy       Date:  2018-08-31

2.  FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals.

Authors:  Laurent Portel; Eric Parrat; Cécilia Nocent-Ejnaini; Gilles Mangiapan; Anne Prud'homme; Jean-Philippe Oster; Corinne Aperre de Vecchi; Cyril Maurer; Chantal Raherison; Didier Debieuvre
Journal:  ERJ Open Res       Date:  2019-10-30

Review 3.  The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma.

Authors:  Sang-Heon Kim; Hyun Lee; So-Young Park; So Young Park; Woo-Jung Song; Joo-Hee Kim; Heung-Woo Park; You Sook Cho; Ho Joo Yoon
Journal:  Korean J Intern Med       Date:  2022-02-28       Impact factor: 2.884

4.  Longitudinal follow-up of the asthma status in a French-Canadian cohort.

Authors:  Marie-Eve Lavoie; Jolyane Meloche; Anne-Marie Boucher-Lafleur; Paul Bégin; Charles Morin; Louis-Philippe Boulet; Anne-Marie Madore; Catherine Laprise
Journal:  Sci Rep       Date:  2022-08-13       Impact factor: 4.996

5.  Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials?

Authors:  Laurie Pahus; Carey Meredith Suehs; Laurence Halimi; Arnaud Bourdin; Pascal Chanez; Dany Jaffuel; Julie Marciano; Anne-Sophie Gamez; Isabelle Vachier; Nicolas Molinari
Journal:  BMC Med Ethics       Date:  2020-08-13       Impact factor: 2.652

Review 6.  Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.

Authors:  Victoria S Benson; Sylvia Hartl; Neil Barnes; Nicholas Galwey; Melissa K Van Dyke; Namhee Kwon
Journal:  Eur Respir J       Date:  2022-01-13       Impact factor: 16.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.